ERBB2 and intrahepatic cholangiocarcinoma: In BTC, the incidence of HER2 overexpression is around 10–16% in gallbladder cancer, 5–9% in extrahepatic cholangiocarcinoma and 1% in intrahepatic cholangiocarcinoma, although reports vary [22,23,24].